A subsequent, larger meta-analysis showed that anti-PD-1/PD-L1 was associated with a 5-6 fold higher risk of pneumonitis compared with cytotoxic chemotherapy (Huang et al., 2019). Here, PDCD1 is linked to pneumonitis.